Posts

Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress – Eikon Therapeutics Clinical Pipeline Updates at ESMO 26 Congress in Madrid, Spain

on

Ipsen acquires Kartos for $1.75B to add Jakafi combo therapy navtemadlin in myelofibrosis

on

GSK to Acquire Nuvalent for $10.6 Billion, Marking Its Largest Oncology Push in a Decade

on

WOW!: RevMed and Tango’s pancreatic cancer combo achieves 92% response

on

Agios Licenses Oscotec Blood Disorder Drug Cevidoplenib in $165M Deal Despite Phase 2 Setback

on

Eikon Therapeutics Presents Data on Clinical-Stage Programs at ASCO 2026

on

Eli Lilly Acquires Ajax Therapeutics for $2.3B to Advance Next-Generation JAK Inhibitor

on

Cardiff Oncology Presents Preclinical Data on Onvansertib Combined with HER2-Targeted ADC at 2026 AACR Annual Meeting

on

Dual-Action Molecule and Drug Combos Show Promise in Treating Multiple Cancers in Mice Models

on

Ipsen Withdraws Tazverik from Market Due to Secondary Malignancy Safety Concerns

on

Enliven’s Phase 1b ELVN‑001 leukemia pill shows competitive efficacy vs. Novartis and Terns CML TKIs

on

Enliven’s Phase 1b ELVN‑001 leukemia pill shows competitive efficacy vs. Novartis and Terns CML TKIs

on

Enliven’s Phase 1b ELVN‑001 leukemia pill shows competitive efficacy vs. Novartis and Terns CML TKIs

on

Enliven’s Phase 1b ELVN‑001 leukemia pill shows competitive efficacy vs. Novartis and Terns CML TKIs

on

Enliven’s Phase 1b ELVN‑001 leukemia pill shows competitive efficacy vs. Novartis and Terns CML TKIs

on

AstraZeneca Pays $100M Upfront, Up to $2B Total for Jacobio's Pan-KRAS Inhibitor JAB-23E73

on

Acrivon Therapeutics Showcases AP3 Platform and Preclinical Data for ACR-2316 with Three Poster Presentations at AACR-NCI-EORTC 2025

on

Zenas BioPharma Inks $2 Billion+ Licensing Deal With InnoCare for Autoimmune Drug Candidates

on

Odyssey Therapeutics Secures $213M Series D to Accelerate Autoimmune Clinical Portfolio

on

Treeline Announces $200M Funding Boost, Moves Three Cancer Drugs into Clinic

on